Navigation Links
Biotech Pioneer Discusses Breakthrough in Osteoporosis Treatment

Deltanoid founder and CEO Hector DeLuca has discovered and characterized a promising chemically modified Vitamin D compound, 2MD, which reverses the effects of osteoporosis. In animal studies, 2MD increases bone growth while leaving blood calcium levels unchanged even at doses 3,000 times the level of other compounds.

According to DeLuca, Vitamin Ds main job is to regulate calcium levels......

Full article >>> s willing to acquire rights for technologies in very early stages of development. They now want to see proof of principle and more developed products before they agree to deals, he said.

As a result, Deltanoids strategy will focus on developing university technology to the stage where large pharmaceutical companies are then willing to sign on. Deltanoid will not market drugs or take them......

Full article >>>
'"/>

Source:wistechnology.com By John Keach 04/15/03


Related biology technology :

1. Biotech officials praise focus of new venture fund
2. Biotech executive books a career flight thats closer to home
3. Gala Biotech among companies sold for $3.3 billion
4. Biotech with Madison ties raises $21M in capital
5. Biotech firm uses live heart tissue in drug screens
6. Biotech talent drew venture-funded firm to Madison
7. Biotech firm has strokes, Alzheimers in its sights
8. 42 days until the 2006 Olympics of Biotechnology in Chicago
9. Biotech crops gaining acceptance, but their full promise has yet to be fulfilled
10. Biotech leads list of top U.S. companies to work for
11. Biotech flourishes in 2005 while Big Pharma is on the decline
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/23/2016)... ... June 23, 2016 , ... STACS DNA Inc., the sample ... the Arkansas State Crime Laboratory, has joined STACS DNA as a Field Application Specialist. ... said Jocelyn Tremblay, President and COO of STACS DNA. “In further expanding our capacity ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
(Date:6/23/2016)... 23, 2016 Andrew ... http://doi.org/10.17925/OHR.2016.12.01.22 Published recently in ... journal from touchONCOLOGY, Andrew D Zelenetz , ... cancer care is placing an increasing burden on ... biologic therapies. With the patents on many biologics ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... the Pennsylvania Convention Center and will showcase its product’s latest features from June ... be presenting a scientific poster on Disrupting Clinical Trials in The Cloud during ...
Breaking Biology Technology:
(Date:4/15/2016)... Research and Markets has announced ... 2016-2020,"  report to their offering.  , ... global gait biometrics market is expected to grow ... 2016-2020. Gait analysis generates multiple variables ... to compute factors that are not or cannot ...
(Date:3/31/2016)...  Genomics firm Nabsys has completed a financial  restructuring ... , M.D., who returned to the company in October ... team, including Chief Technology Officer, John Oliver , ... and Vice President of Software and Informatics, Michael ... Dr. Bready served as CEO of Nabsys from 2005-2014 ...
(Date:3/22/2016)... PROVO and SANDY, Utah ... Ontario (NSO), which operates the highest sample volume laboratory ... and Tute Genomics and UNIConnect, leaders in clinical sequencing ... announced the launch of a project to establish the ... panel. NSO has been contracted by ...
Breaking Biology News(10 mins):